Some Pneumonia Patients See Benefit from Shorter Antibiotic Treatment Plans, Study Finds

Only about a tenth of patients across the study period qualified for the shorter antibiotic regimen, but they saw similar results as those treated with a longer regimen.

Matt MacKenzie

April 17, 2026

Key Highlights

Shorter antibiotic courses (3-4 days) may be as safe as longer treatments for certain stable CAP patients.
Study analyzed data from 67 Michigan hospitals, focusing on non-ICU patients after three days of stability.
Risks of mortality, readmission, urgent visits, and C. difficile infection were similar between short- and long-course therapies.
Most patients in the study had underlying health conditions, limiting generalizability to all CAP cases.
Further research is needed to determine optimal treatment durations for diverse patient populations.

A new report in the Annals of Internal Medicine found that “shorter antibiotic treatment durations may be as safe and effective as longer ones for a small subset of patients hospitalized with community-acquired pneumonia (CAP).” CIDRAP has the news.

A team of researchers analyzed data from 67 Michigan hospitals from 2017 through 2014 to compare outcomes in CAP patients with shorter versus longer antibiotic courses. Only around 10% of the people hospitalized with CAP over the study period met the “eligibility criteria for short-course therapy, with most being excluded because of underlying comorbidities.”

7.9% of those patients received “three-to-four days of antibiotics, and the median antibiotic duration was 7 days.” Thirty-day adjusted risk ratios for short- versus long-course antibiotic therapy were “0.89 for mortality, 1.07 for readmission, 0.94 for urgent visit, and 1.01 for C difficile infection. Adverse events were similar in both groups.”

According to the study authors, the results are “most applicable to non-intensive care unit CAP patients who are clinically stable after three days. But the study has identified critical research questions, they add.”